Paul received his M.D. with distinction in research at the Univ. of Rochester, completed Med/Peds residency at Emory University, followed by Adult and Pediatric Endocrinology fellowships at UPMC and Children’s Hospital of Pittsburgh. Paul served as CMO of JDRF and Chair of the Diabetes Center of Excellence at Quintiles. He currently leads the development program at Lexicon Pharmaceuticals for Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor as adjunct to insulin therapy in type 1 diabetes.

Zoran Antonijevic is Vice President of Statistical Consulting at Abond CRO. He held executive positions in Pharmaceutical Companies and CROs and has designed more than 100 clinical trials in numerous therapeutic areas, many of which included adaptive designs. Zoran is a long-time Chair and leader of the DIA Innovative Designs Scientific Working Group. He has authored numerous papers and scientific presentations and was editor of books “Optimization of Pharmaceutical R&D Programs and Portfolios” and, with Bob Beckman, “Platform Trials in Drug Development: Umbrella Trials and Basket Trials”.